Perennial Malaria Chemoprevention (PMC) Effect Study - Trial NCT06155448
Access comprehensive clinical trial information for NCT06155448 through Pure Global AI's free database. This phase not specified trial is sponsored by Malaria Consortium and is currently Recruitment Completed. The study focuses on Malaria. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Malaria Consortium
Timeline & Enrollment
N/A
Aug 08, 2023
Dec 01, 2026
Primary Outcome
. Incidence rate of clinical malaria,Protective effectiveness of SP
Summary
The Malaria Consortium Nigeria (MC) will coordinate a trial of PMC in Osun State, Nigeria
 with strategic support from the National Malaria Elimination Programme of the Government of
 Nigeria (NMEP) and financial support from the BMGF. The primary purpose of the study is to
 provide evidence of the impact of PMC on malaria burden and related clinical outcomes, and
 its operational feasibility for policy decision and the inclusion of PMC into upcoming
 programme and funding cycles for its National Malaria Control Strategic Plan. The objectives
 are:
 
 1. To evaluate the impact of PMC in children aged 2-18 months on key child health outcomes
 including malaria burden, hospitalisations, and anaemia.
 
 2. To describe indicators of operational feasibility of PMC by identification and
 measurement of key determinants of successful uptake and implementation of PMC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06155448
Non-Device Trial